{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-027849","form_type":"8-K","ticker":"INFU","cik":"0001337013","company_name":"InfuSystem Holdings, Inc","filed_at":"2024-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.010041+00:00","generated_at":"2026-06-01T04:48:06.606559+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"InfuSystem projects 2024 revenue of $134.2M and adjusted EBITDA of $26.5M","bullets":["2023 revenue $125.8M (12% CAGR over 5 years); adjusted EBITDA $22.4M.","Q1 2024 revenue $32.0M; adjusted EBITDA $3.9M (vs. $4.2M in Q1 2023).","Guidance: 2024 revenue ~$134.2M (high single-digit growth); adjusted EBITDA ~$26.5M (margin 19.7%).","Patient Services gross margin stable at ~63%; Device Solutions gross margin declined to 31.5% (TTM).","Capital allocation: $20M share repurchase program; net leverage 1.32x; NOLs $26.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-027849","json":"https://secwatch.observer/filing/0001628280-24-027849.json","markdown":"https://secwatch.observer/filing/0001628280-24-027849.md","text":"https://secwatch.observer/filing/0001628280-24-027849.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1337013/000162828024027849/0001628280-24-027849-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1337013/000162828024027849/infu-20240612.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:48:06.606559+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}